Change of Nrf2 expression in rat hippocampus in a model of chronic cerebral hypoperfusion

References

• de la Torre JC. Alzheimer's disease is a vasocognopathy: a new term to describe its nature. Neurol Res 2004;26:517–24.
   PubMed Web of Science ®Google Scholar
• De Jong GI, De Vos RA, Steur EN, Luiten PG. Cerebrovascular hypoperfusion: a risk factor for Alzheimer's disease? Animal model and postmortem human studies. Ann N Y Acad Sci 1997;826:56–74.
   PubMed Web of Science ®Google Scholar
• Ruitenberg A, den Heijer T, Bakker SL, Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 2005;57:789–94
   PubMed Web of Science ®Google Scholar
• Sarti C, Pantoni L, Bartolini L, Inzitari D. Cognitive impairment and chronic cerebral hypoperfusion: what can be learned from experimental models. J Neurol Sci 2002; 203–4:263–6.
   Web of Science ®Google Scholar
• Scheel P, Puls I, Becker G, Schoning M. Volume reduction in cerebral blood flow in patients with vascular dementia. Lancet 1999;354:2137.
   PubMed Web of Science ®Google Scholar
• de la Torre JC. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol Aging 2000;21:331–42.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang J. Cerebral hypoperfusion and cognitive impairment: the pathogenic role of vascular oxidative stress. Int J Neurosci 2012;122:494–9.
   PubMed Web of Science ®Google Scholar
• Huang L, He Z, Guo L, Wang H. Improvement of cognitive deficit and neuronal damage in rats with chronic cerebral ischemia via relative long-term inhibition of rho-kinase. Cell Mol Neurobiol 2008;28:757–68.
   PubMed Web of Science ®Google Scholar
• Yan X, Zhang JJ, Li X, Green tea polyphenols inhibit cognitive impairment induced by chronic cerebral hypoperfusion via modulating oxidative stress. J Nutr Biochem 2009;21:741–8.
   PubMed Web of Science ®Google Scholar
• He XL, Wang YH, Gao M, Baicalein protects rat brain mitochondria against chronic cerebral hypoperfusion-induced oxidative damage. Brain Res 2009;1249:212–21.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Yamamoto M. Nrf2–Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul 2006;46:113–40.
   PubMedGoogle Scholar
• Johnson JA, Johnson DA, Kraft AD, The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci 2008;1147:61–9.
   PubMed Web of Science ®Google Scholar
• de Vries HE, Witte M, Hondius D, Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease? Free Radic Biol Med 2008;45:1375–83.
   PubMed Web of Science ®Google Scholar
• Itoh K, Wakabayashi N, Katoh Y, Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999;13:76–86.
   PubMed Web of Science ®Google Scholar
• Calkins MJ, Jakel RJ, Johnson DA, Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci USA 2005;102:244–9.
   PubMed Web of Science ®Google Scholar
• Shih AY, Imbeault S, Barakauskas V, Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J Biol Chem 2005;280:22925–36.
   PubMed Web of Science ®Google Scholar
• Satoh T, Okamoto SI, Cui J, Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers. Proc Natl Acad Sci USA 2006;103:768–73.
   PubMed Web of Science ®Google Scholar
• Satoh T, Kosaka K, Itoh K, Carnosic acid, a catechol-type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1. J Neurochem 2008;104:1116–31.
   PubMed Web of Science ®Google Scholar
• Hickenbottom SL, Grotta JC, Strong R, Nuclear factor-kappaB and cell death after experimental intracerebral hemorrhage in rats. Stroke. 1999;30:2472–7, 2477–8
   PubMed Web of Science ®Google Scholar
• Gorelick PB, Scuteri A, Black SE, Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:2672–713.
   PubMed Web of Science ®Google Scholar
• Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 2001;64:575–611.
   PubMed Web of Science ®Google Scholar
• Farkas E, Luiten PG, Bari F. Permanent, bilateral common carotid artery occlusion in the rat: a model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Res Rev 2007;54:162–80.
   PubMedGoogle Scholar
• Jiwa NS, Garrard P, Hainsworth AH. Experimental models of vascular dementia and vascular cognitive impairment: a systematic review. J Neurochem 2010;115:814–28.
   PubMed Web of Science ®Google Scholar
• Ohta H, Nishikawa H, Kimura H, Chronic cerebral hypoperfusion by permanent internal carotid ligation produces learning impairment without brain damage in rats. Neuroscience 1997;79:1039–50.
   PubMed Web of Science ®Google Scholar
• Otori T, Katsumata T, Muramatsu H, Long-term measurement of cerebral blood flow and metabolism in a rat chronic hypoperfusion model. Clin Exp Pharmacol Physiol 2003;30:266–72.
   PubMed Web of Science ®Google Scholar
• Tsuchiya M, Sako K, Yura S, Yonemasu Y. Cerebral blood flow and histopathological changes following permanent bilateral carotid artery ligation in Wistar rats. Exp Brain Res 1992;89:87–92.
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Sultana R. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J Alzheimers Dis 2007;12:61–72.
   PubMed Web of Science ®Google Scholar
• Hensley K, Maidt ML, Yu Z, Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 1998;18:8126–32.
   PubMed Web of Science ®Google Scholar
• Calkins MJ, Johnson DA, Townsend JA, The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal 2009;11:497–508.
   PubMed Web of Science ®Google Scholar
• Scapagnini G, Vasto S, Abraham NG, Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol 2011;44:192–201.
   PubMed Web of Science ®Google Scholar
• Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med 2004;Suppl(S18–25).
   Google Scholar
• Barhwal K, Hota SK, Jain V, Acetyl-l-carnitine (ALCAR) prevents hypobaric hypoxia-induced spatial memory impairment through extracellular related kinase-mediated nuclear factor erythroid 2-related factor 2 phosphorylation. Neuroscience. 2009;161:501–14.
   PubMed Web of Science ®Google Scholar
• Liao Y, Wang R, Tang XC. Centrophenoxine improves chronic cerebral ischemia induced cognitive deficit and neuronal degeneration in rats. Acta Pharmacol Sin 2004;25:1590–6.
   Google Scholar
• Shih AY, Johnson DA, Wong G, Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 2003;23:3394–406.
   PubMed Web of Science ®Google Scholar
• Fahey JW, Talalay P. Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food Chem Toxicol 1999;37:973–9.
   PubMed Web of Science ®Google Scholar
• Zhao J, Kobori N, Aronowski J, Dash PK. Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neurosci Lett 2006;393:108–12.
   PubMed Web of Science ®Google Scholar